10 September 2024 · 1 min read
$120M Alert: Another significant funding round in AI-driven drug discovery, this time with Lilly...
Another significant $120M funding round has landed in AI-driven drug discovery, this time with Lilly leading alongside Nvidia and key VC funds. I'm optimistic that we could be witnessing the birth of the next Amgen, Genentech, or Biogen — powered by AI.
Filed under Tech Bio
$120M Alert: Another significant funding round in AI-driven drug discovery, this time with Lilly leading the way!
The surge in investments for AI-enabled biotech and techbio companies continues strong. Recent rounds include Formation Bio, Xaira Therapeutics, and now, Lilly - alongside Nvidia and key VC funds - investing $120M into a company focused on GPCR targets, leveraging a fully virtual screening approach.
Despite challenges faced by companies like Recursion, I believe this is just the beginning. We might be witnessing the birth of the next Amgen, Genentech, or Biogen - the giants that emerged from the molecular biology revolution. Could AI be the driving force behind the next wave of biopharma innovation? I'm optimistic.
Related insights
16 Dec 2025
OpenAI is among the backers of a biotech founded in 2024 that is already valued at $1.3B.
7 Apr 2026
Anthropic buys Coefficient Bio: why the scientific decision layer matters
26 Mar 2026
Earendil Labs just raised $787M for AI-driven biologics. The largest AI biotech round of 2026 so far.
10 Mar 2026
AI drug discovery benchmarks: why pharma needs model evaluation discipline